Goodwin Advises Keensight Capital and Bedfont Scientific on the Acquisition of coVita
The Private Equity team advised Keensight Capital and Bedfont® Scientific Limited (“Bedfont”) on their acquisition of coVita, a leader in the medical diagnostic equipment space. The acquisition positions Bedfont to further penetrate the US market with its innovative breath analysis devices, including the NObreath® Fractional exhaled Nitric Oxide device. As Bedfont puts more focus on clinical research, a US base provides access to a major clinical research market and enables localized distribution, training, and technical support.
Keensight Capital is a European growth buyout investor with deep expertise in technology and healthcare. Keensight Capital partners with the management teams of fast-growing and profitable companies providing capital, strategic guidance, and operational support.
Bedfont Scientific Limited specializes in designing and manufacturing breath analysis medical devices. Using innovative technology, Bedfont provides cutting-edge medical devices at affordable prices to improve accessibility and healthcare standards worldwide.
A cross-border team of Goodwin lawyers was led by Ed Amer in Boston and Jamie Holdoway in London, and included Michael Cain, Michael Parisse, Frederick Howell, Marcus Walford, and Eimear Devaney (Corporate), Matt Wetzel, Jonathan Ishee, Dustin Schaefer, and Michael Paluzzi (HC Regulatory), Steven Tjoe and Javier Gonzalez Rivera (FDA), Steve Charkoudian and Lauren Avery (IP), Ed Holzwanger and Ana Alvarado (L&E), Malhar Naik (Benefits), Jake Osborn and Nate Cunningham (Global Trade), and Janet Andolina and Benjamin Gossels (Tax).
For more information on the deal, please read the press release.